Enhancing GABA inhibition is the next generation of medications for essential tremor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

γ-Aminobutyric acid (GABA) is the most prevalent inhibitory CNS neurotransmitter. Activating GABA-A receptors hyperpolarizes cells via Cl influx, which inhibits action potentials. Although the exact pathophysiologies of tremor are incompletely understood, proposed neuroanatomy extensively implicates GABA pathways. Pathological studies and imaging studies also show GABA abnormalities in patients with ET. Most importantly, medications that activate GABA-A receptors, such as primidone, often improve tremor. Ongoing clinical trials and physiology research should further refine potential future GABAergic targets and treatments, which are currently the most promising targets for pharmacological intervention.

Original languageEnglish (US)
Title of host publicationInternational Review of Neurobiology
PublisherAcademic Press
DOIs
StateAccepted/In press - 2022

Publication series

NameInternational Review of Neurobiology
ISSN (Print)0074-7742
ISSN (Electronic)2162-5514

Keywords

  • Barbiturates
  • Benzodiazepines
  • Cerebellum
  • Essential tremor
  • Ethanol
  • Purkinje cells
  • γ-Aminobutyric acid (GABA)

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Enhancing GABA inhibition is the next generation of medications for essential tremor'. Together they form a unique fingerprint.

Cite this